trending Market Intelligence /marketintelligence/en/news-insights/trending/dDYHec31IEuqMm9J0m6rTw2 content esgSubNav
In This List

IntelGenx, RedHill sign agreement to commercialize migraine drug in South Korea

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


IntelGenx, RedHill sign agreement to commercialize migraine drug in South Korea

IntelGenx Technologies Corp. and RedHill Biopharma Ltd. signed an exclusive license agreement with Pharmatronic Co. for the commercialization of RIZAPORT in South Korea.

RedHill granted Pharmatronic Co. the exclusive rights to register and commercialize the drug in South Korea. IntelGenx and RedHill will receive an upfront payment along with additional milestone payments upon achievement of certain predefined regulatory and commercial targets, as well as tiered royalties.

Further financial terms of the agreement were not disclosed.

The initial term of the definitive agreement is for 10 years from the date of first commercial sale and shall automatically renew for an additional two-year term.

Commercial launch in South Korea is estimated to take place in the first quarter of 2019.

IntelGenx and RedHill are expected to re-submit a new drug application for the drug to the U.S. FDA in the first half of 2017, and receive a new prescription drug user fee act date. They are currently in discussions with potential commercialization partners for the U.S. market.